Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company is headquartered in Carlton, Australia.
| Revenue (TTM) | $16.28M |
| Gross Profit (TTM) | $-22.22M |
| EBITDA | $-39.18M |
| Operating Margin | -423.70% |
| Return on Equity | -92.10% |
| Return on Assets | -28.30% |
| Revenue/Share (TTM) | $2.10 |
| Book Value | $3.12 |
| Price-to-Book | 1.12 |
| Price-to-Sales (TTM) | 2.05 |
| EV/Revenue | 5.66 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 154.50% |
| Shares Outstanding | $7.88M |
| Float | $8.29M |
| % Insiders | 0.00% |
| % Institutions | 2.54% |
Volatility is currently expanding
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (the primary endpoint) in 90% of evaluable subjects (18/20)
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
